Tenapanor Improves Abdominal Symptoms Irrespective of Changes in Complete Spontaneous Bowel Movement Frequency in Adults with Irritable Bowel Syndrome with Constipation
Tenapanor was observed to improve abdominal symptoms independent of its effect on bowel symptoms in adults with IBS-C.
Authors
- Lucinda A. Harris
- Gregory S. Sayuk (ORCID: https://orcid.org/0000-0003-1586-199X)
- Anthony J Lembo (ORCID: https://orcid.org/0000-0002-4479-1188)
- Suling Zhao (ORCID: https://orcid.org/0009-0006-8356-876X)
- Brooks D. Cash (ORCID: https://orcid.org/0000-0002-8497-3349)
- David P. Rosenbaum (ORCID: https://orcid.org/0000-0002-9371-391X)
- Darren M. Brenner (ORCID: https://orcid.org/0000-0002-8577-7278)
- Jill K. Deutsch
- Yang Yang (ORCID: https://orcid.org/0000-0002-4956-2034)
- Nitin K. Ahuja (ORCID: https://orcid.org/0000-0002-0283-5488)
Institutions
- Northwestern University (US)
- Cleveland Clinic (US)
- Yale New Haven Hospital (US)
- Washington University in St. Louis (US)
- Mayo Clinic in Arizona (US)
- Ardelyx (United States) (US)
- University of Pennsylvania (US)
- The University of Texas Health Science Center at Houston (US)
Publication Details
- Journal
- Digestive Diseases
- Published
- 2024-12-19
- DOI
- https://doi.org/10.1159/000543166
- Citations
- 4
- Primary Topic
- Gastrointestinal motility and disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.86
Funders
- Alnylam Pharmaceuticals
- Ironwood Pharmaceuticals, Incorporated
- Vanda Pharmaceuticals